Insys's medicinal cannabis diphenol has been recognized by FDA as an orphan drug

Source: insys therapeutics, a professional pharmaceutical company developing innovative drugs and new drug delivery systems under the China Council for the promotion of drugs on July 3, 2014, announced on Wednesday that the U.S Food and drug administration has granted it the status of orphan drug of medicinal cannabis bisphenol (CBD) for the treatment of Dravet syndrome, a rare childhood epilepsy The company said it expects to submit its research drug application (ind) to CBD in the second half of 2014 Insys' plant for THC and CBD is located in round rock, Texas It has passed FDA inspection and been approved by DEA The company said it believed it was the only U.S company that could produce medicinal cannabis bisphenol and expand its production Michael babich, President and CEO of the company, said, "there is no drug to cure this catastrophic epilepsy at present It is obvious that the drug we received today for orphans of CBD identified the unmet needs Our medicinal CBD is an alternative to marijuana cultivation and we believe it will provide significant medical benefits and better address unmet needs across multiple indications, including Dravet syndrome " In addition to Dravet syndrome, insys plans to develop its orphan drug approved medicinal CBD for the treatment of another rare childhood epilepsy, Lennox Gastaut syndrome The company is also evaluating the potential of medicinal CBD for several other indications Original link: http://www.rttnews.com/2344553/insys-gets-fda-orphan-drug-design-for-pharmaceutical-cannabidiol.aspx